Page last updated: 2024-11-13

withanoside iv

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

withanoside IV: a withanolide glycoside from Ashwagantha (root of Withania somnifera), an Ayurvedic medicine; improves hindlimb function by facilitating axonal growth and increase in peripheral nervous system myelin level after spinal cord injury [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
WithaniagenusA plant genus of the family SOLANACEAE. Members contain withanolides. Withania somnifera is the source of ashwagandha and aswal.[MeSH]SolanaceaeA plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH]

Cross-References

ID SourceID
PubMed CID71312551
SCHEMBL ID16365858
MeSH IDM0515058

Synonyms (16)

Synonym
362472-81-9
withanoside iv
unii-156gup486t
ergosta-5,24-dien-26-oic acid, 3-((6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy)-1,22,27-trihydroxy-, sigma-lactone, (1alpha,3beta,22r)-
156GUP486T ,
withanoside iv, (+)-
ergosta-5,24-dien-26-oic acid, 3-((6-o-.beta.-d-glucopyranosyl-.beta.-d-glucopyranosyl)oxy)-1,22,27-trihydroxy-, .sigma.-lactone, (1.alpha.,3.beta.,22r)-
withanoside iv [usp-rs]
(1alpha,3beta,22r)-1,26-dihydroxy-27-oxo-22,27-epoxyergosta-5,24-dien-3-yl 6-o-beta-d-glucopyranosyl-beta-d-glucopyranoside
DTXSID40746874
SCHEMBL16365858
withanoside iv, analytical standard
withanoside iv, united states pharmacopeia (usp) reference standard
(2r)-2-[(1s)-1-[(1s,3r,8s,9s,10r,13s,14s,17r)-1-hydroxy-10,13-dimethyl-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]
Q27251700
AKOS040762510

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Oral treatment with withanoside IV improved locomotor functions in mice with SCI."( [Overcoming several neurodegenerative diseases by traditional medicines: the development of therapeutic medicines and unraveling pathophysiological mechanisms].
Tohda, C, 2008
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.16 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index32.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]